Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group

In English

Författare

  • Richard M. Brohet
  • David E. Goldgar
  • Douglas F. Easton
  • Antonis C. Antoniou
  • Nadine Andrieu
  • Jenny Chang-Claude
  • Susan Peock
  • Rosalind A. Eeles
  • Margaret Cook
  • Carol Chu
  • Catherine Nogues
  • Christine Lasset
  • Pascaline Berthet
  • Hanne Meijers-Heijboer
  • Anne-Marie Gerdes
  • Håkan Olsson
  • Trinidad Caldes
  • Flora E. van Leeuwen
  • Matti A. Rookus
Visa allt

Summary, in English

Purpose Earlier studies have shown that endogenous gonadal hormones play an important role in the etiology of breast cancer among BRCA1/ 2 mutation carriers. So far, little is known about the safety of exogenous hormonal use in mutation carriers. In this study, we examined the association between oral contraceptive use and risk of breast cancer among BRCA1/ 2 carriers. Patients and Methods In the International BRCA1/ 2 Carrier Cohort study ( IBCCS), a retrospective cohort of 1,593 BRCA1/ 2 mutation carriers was analyzed with a weighted Cox regression analysis. Results We found an increased risk of breast cancer for BRCA1/ 2 mutation carriers who ever used oral contraceptives ( adjusted hazard ratio [ HR] = 1.47; 95% CI, 1.16 to 1.87). HRs did not vary according to time since stopping use, age at start, or calendar year at start. However, a longer duration of use, especially before first full- term pregnancy, was associated with an increased risk of breast cancer for both BRCA1 and BRCA2 mutation carriers ( 4 or more years of use before first full-term pregnancy: HR = 1.49 [ 95% CI, 1.05 to 2.11] for BRCA1 carriers and HR = 2.58 [ 95% CI, 1.21 to 5.49] for BRCA2 carriers). Conclusion No evidence was found among BRCA1/ 2 mutation carriers that current use of oral contraceptives is associated with risk of breast cancer more strongly than is past use, as is found in the general population. However, duration of use, especially before first full- term pregnancy, may be associated with an increasing risk of breast cancer among both BRCA1 and BRCA2 mutation carriers.

Avdelning/ar

Publiceringsår

2007

Språk

Engelska

Sidor

3831-3836

Publikation/Tidskrift/Serie

Journal of Clinical Oncology

Volym

25

Issue

25

Dokumenttyp

Artikel i tidskrift

Förlag

American Society of Clinical Oncology

Ämne

  • Cancer and Oncology

Nyckelord

  • Oral Contraceptives Breast Cancer International BRCA1/2 EMBRACE GENEPSO GEO-HEBON IBCCS

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1527-7755